An unnamed care provider has added $20m to the $80m the software-based therapeutics developer received from investors including Novartis and SoftBank in December.
Pear Therapeutics, a US-headquartered developer of digital therapeutics, has added $20m to a series D round backed by pharmaceutical firm Novartis and telecommunications and internet group SoftBank that now totals $100m.
An undisclosed US-based healthcare system provided an extra $20m, following an $80m close in December 2020 led by SoftBank’s Vision Fund 2 that included Novartis, Singaporean state-owned investment firm Temasek and EDBI, an investment subsidiary of the Singapore Economic Development Board.
The first tranche also featured 5AM Ventures,…
